ClinicalTrials.gg
CompletedNCT04408924CYCLONE 1Updated Jun 25, 2024Results posted

Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer

A Phase 2 interventional study of Abemaciclib in Metastatic Castration-Resistant Prostate Cancer, sponsored by Eli Lilly and Company. Completed at 14 sites in 3 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-25.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing abemaciclib in Prostatic Neoplasms — 1 open to participants now, 3 under way, 2 of them phase 3. abemaciclib · Prostatic Neoplasms.

Enrollment
3rd of 10
44 · median 15
Started
2021
with 2 others
Phase 2
5 of 10
none open now
Registered
4th of 10
by date
Lead sponsor
4 of 10
Eli Lilly and Company

Among the 10 studies testing abemaciclib in Prostatic Neoplasms, this one is the 3rd largest by enrollment, is one of 3 that started in 2021, is one of 5 in phase 2, and was the 4th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

1 of the 10 studies testing abemaciclib in Prostatic Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About abemaciclib

abemaciclib: first FDA approval 2017 (VERZENIO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing abemaciclib in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The study will evaluate how safe and effective abemaciclib is when given to participants whose metastatic prostate cancer progresses after they had received several previous treatments.

03

Conditions studied

  • Metastatic Castration-Resistant Prostate Cancer

Browse trials for

Keywords

  • mCRPC
  • CDK4
  • CDK6
  • CDK4/6
  • CDK4&6 inhibitor
  • CDK4/6 inhibitor
  • LY2835219
  • CYCLONE 1
  • CYCLONE1
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must have prostate cancer for which castration (medical or surgical) is no longer effective (castration-resistant).
  • Participant must have disease spread to soft tissue that is measurable.
  • Participant must have documented evidence of progressive disease by PSA test or imaging.
  • Participant must have previously received at least one of the following treatment: abiraterone acetate, apalutamide, darolutamide or enzalutamide.
  • Participant must have previously received chemotherapy with docetaxel and cabazitaxel.
  • Participant must be willing and amenable to undergo a of tumor tissue (or able to provide adequate archived tumor tissue sample) and to provide blood for research.
  • Participant must have good physical functioning ability and adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Participant must not have received more than 3 therapy regimens for castration-resistant prostate cancer (NOTE: GnRHa, first-generation antiandrogens (flutamide, nilutamide, or bicalutamide), diethylstilbestrol (DES) (or other estrogens), , ketoconazole, and bone loss-prevention will not count as systemic therapy regimens.
  • Participants must not have previously received abemaciclib or any cyclin-dependent kinase (CDK)4 and/or CDK6 inhibitors.
  • Participants must not have serious and/or uncontrolled preexisting medical condition(s) including but not limited to severe renal impairment, severe hepatic impairment, interstitial lung disease (ILD)/pneumonitis, severe dyspnea at rest or requiring oxygen therapy or other serious preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study.
  • Participants must not have, or suspected to have, .
  • Participants must not have untreated spinal cord compression, evidence of spinal metastases with risk of spinal compression or structurally unstable bone lesions suggesting impending fracture.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    200 milligram (mg) Abemaciclib Twice Daily

    Participants received 200 mg abemaciclib administered orally twice daily on a continuous dosing schedule (28-day cycle) until symptomatic and/or radiographic progression, unacceptable toxicity, or until another discontinuation criterion is met.

    Drug: Abemaciclib

Interventions

  • Administered orally

    Also known as: LY2835219

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Confirmed Objective Response (Objective Response Rate [ORR])

    ORR is defined as the percentage of participants with a confirmed complete response (CR) or confirmed partial response (PR) in soft tissue per response evaluation criteria in solid tumors (RECIST) version 1.1 and do not have concurrent bone progression per Prostate Cancer Clinical Trials Working Group 3 (PCWG3), as assessed by the investigator. ORR = (participants with confirmed CR and no bone progression) + (participants with confirmed PR and no bone progression) x 100 / all treated participants.

    Time frame: From Date of First Dose until Objective Progression (Up To 12.8 Months)

Secondary outcomes

  1. Radiographic Progression-Free Survival (rPFS)

    The rPFS time is measured from the date of first dose to the earliest date of investigator-assessed radiographic progression per RECIST 1.1 for soft tissue and PCWG3 criteria for bone, or death from any cause, whichever occurred first. Participants who have neither progressed nor died will be censored at the day of their last radiographic tumor assessment (if available) or date of first dose if no post initiation (i.e., postbaseline) radiographic assessment is available.

    Time frame: From Date of First Dose until Objective Progression or Death from Any Cause (Up To 12.8 Months)

  2. Overall Survival (OS)

    OS time is measured from the date of first dose to the date of death from any cause. If the participant was alive or lost to follow-up at the time of data analysis, OS data were censored on the last date the participant was known to be alive.

    Time frame: From Date of First Dose until Date of Death from Any Cause (Up To 28 Months)

  3. Duration of Response (DoR)

    DoR is measured only for confirmed responders (participants with a confirmed soft tissue best overall response of CR or PR per RECIST 1.1 no concurrent bone progression per PCWG3). It is measured from the date of first evidence of soft tissue CR or PR to the earliest date of investigator-assessed radiographic progression or death from any cause, whichever is earlier.

    Time frame: CR or PR to Disease Progression or Death Due to Any Cause (Up to 12 Months)

  4. Percentage of Participants Achieving CR, PR or Stable Disease (SD) (Disease Control Rate [DCR])

    The DCR is defined as the percentage of participants with confirmed soft tissue best overall response of CR, PR, or stable disease (SD) per RECIST 1.1, and do not have concurrent bone disease progression per PCWG3.

    Time frame: From Date of First Dose until Measured Progressive Disease or Death Due to Any Cause (Up To 12.8 Months)

  5. Time to Prostate-Specific Antigen (PSA) Progression

    Time to PSA progression is defined as the time from the date of treatment initiation to the date of first observation of PSA progression. The PSA progression is defined as a greater than or equal to (\>=) 25 percentage (%) increase and an absolute increase of \>=2 nanogram/milliliter (ng/mL) above the nadir (or baseline value if baseline is the smallest on study), which is confirmed by a second value obtained 3 or more weeks later.

    Time frame: From Date of First Dose until Confirmed PSA Progression (Up To 12.8 Months)

  6. Percentage of Participants Who Achieved Prostate-Specific Antigen (PSA) Response (PSA Response Rate)

    The PSA response rate is defined as the percentage of participants with a reduction in PSA level ≥50% from baseline, confirmed with a second assessment conducted at least 3 weeks later.

    Time frame: From Date of First Dose until Confirmed PSA Progression (Up To 12.8 Months)

  7. Time to Symptomatic Progression

    Time to symptomatic progression is defined as the time from first dose to any of the following (whichever occurred earlier): 1) symptomatic skeletal event, defined as symptomatic fracture, surgery, or radiation to bone, or spinal cord compression; 2) pain progression or worsening of disease-related symptoms requiring initiation of a new systemic anticancer therapy; and 3) development of clinically significant symptoms due to locoregional tumor progression requiring surgical intervention or radiation therapy. For participants who were not known to have symptomatic progression at the time of data analysis, data were censored on the last date at which no symptomatic progression was indicated.

    Time frame: From Date of First Dose until Symptomatic Progression (Up to 12.8 Months)

  8. Pharmacokinetics (PK): Maximum Plasma Concentration at Steady State (Cmax,ss) of Abemaciclib

    PK: Cmax,ss of abemaciclib is reported. The cycle length was 28 days.

    Time frame: Cycle (C) 1 Day (D) 1: Post dose; C1 D15, C2D1, C2D15, C3D1: Pre dose

  9. PK: Minimum/Trough Concentration at Steady State (Cmin,ss) of Abemaciclib

    PK: Cmin,ss of abemaciclib is reported.

    Time frame: C1 D1: Post dose; C1 D15, C2D1, C2D15, C3D1: Pre dose

  10. PK: Maximum Plasma Concentration at Steady State (Cmax,ss) of Abemaciclib Metabolites (Total Active Species)

    PK: Cmax,ss of abemaciclib metabolites (Total Active Species) is reported.

    Time frame: C1 D1: Post dose; C1 D15, C2D1, C2D15, C3D1: Pre dose

  11. PK: Minimum/Trough Concentration at Steady State (Cmin,ss) of Abemaciclib Metabolites (Total Active Species)

    PK: Cmin,ss of abemaciclib metabolites (Total Active Species) is reported.

    Time frame: C1 D1: Post dose; C1 D15, C2D1, C2D15, C3D1: Pre dose

  12. Percentage of Participants With Expression of Ki-67 Proliferation Marker by Immunohistochemistry (IHC)

    Percentage of participants with expression of Ki-67 proliferation marker at baseline by immunohistochemistry. Baseline expression of the Ki-67 proliferation marker was evaluated by IHC utilizing a 20% or higher score to define high Ki-67 expression. The percentage of Ki-67 positive cells was defined by the number of non-apoptotic tumor cells with unequivocal brown nuclear staining (intensities ≥1 using a 0-3 scale) over the total number of non-apoptotic tumor cells. Unit of Measure is percentage of participants with low or high baseline Ki-67 expression.

    Time frame: Baseline

07

Results

Posted May 24, 2023

Participant flow

Participant flow — Overall Study
Milestone200 Milligram (mg) Abemaciclib Twice Daily
Started44
Received at least one dose of study drug44
Completed31
Not completed13
Withdrew: Off treatment on post-treatment-discontinuation follow-up3
Withdrew: Lost to follow-up3
Withdrew: Withdrawal by subject5
Withdrew: Sponsor decision2

Outcome measures

PrimaryPercentage of Participants With Confirmed Objective Response (Objective Response Rate [ORR])

ORR is defined as the percentage of participants with a confirmed complete response (CR) or confirmed partial response (PR) in soft tissue per response evaluation criteria in solid tumors (RECIST) version 1.1 and do not have concurrent bone progression per Prostate Cancer Clinical Trials Working Group 3 (PCWG3), as assessed by the investigator. ORR = (participants with confirmed CR and no bone progression) + (participants with confirmed PR and no bone progression) x 100 / all treated participants.

Time frame:
From Date of First Dose until Objective Progression (Up To 12.8 Months)
Reported as:
Number · percentage of participants
Percentage of Participants With Confirmed Objective Response (Objective Response Rate [ORR])
percentage of participants200 mg Abemaciclib Twice Daily
Percentage of Participants With Confirmed Objective Response (Objective Response Rate [ORR])6.8 (0.0 to 14.3)
SecondaryRadiographic Progression-Free Survival (rPFS)

The rPFS time is measured from the date of first dose to the earliest date of investigator-assessed radiographic progression per RECIST 1.1 for soft tissue and PCWG3 criteria for bone, or death from any cause, whichever occurred first. Participants who have neither progressed nor died will be censored at the day of their last radiographic tumor assessment (if available) or date of first dose if no post initiation (i.e., postbaseline) radiographic assessment is available.

Time frame:
From Date of First Dose until Objective Progression or Death from Any Cause (Up To 12.8 Months)
Reported as:
Median · months
Radiographic Progression-Free Survival (rPFS)
months200 mg Abemaciclib Twice Daily
Radiographic Progression-Free Survival (rPFS)2.7 (1.9 to 3.7)
SecondaryOverall Survival (OS)

OS time is measured from the date of first dose to the date of death from any cause. If the participant was alive or lost to follow-up at the time of data analysis, OS data were censored on the last date the participant was known to be alive.

Time frame:
From Date of First Dose until Date of Death from Any Cause (Up To 28 Months)
Reported as:
Median · months
Overall Survival (OS)
months200 mg Abemaciclib Twice Daily
Overall Survival (OS)8.38 (5.62 to 12.69)
SecondaryDuration of Response (DoR)

DoR is measured only for confirmed responders (participants with a confirmed soft tissue best overall response of CR or PR per RECIST 1.1 no concurrent bone progression per PCWG3). It is measured from the date of first evidence of soft tissue CR or PR to the earliest date of investigator-assessed radiographic progression or death from any cause, whichever is earlier.

Time frame:
CR or PR to Disease Progression or Death Due to Any Cause (Up to 12 Months)
Reported as:
Median · months
Duration of Response (DoR)
months200 mg Abemaciclib Twice Daily
Duration of Response (DoR)NA (3.88 to 11.18)
SecondaryPercentage of Participants Achieving CR, PR or Stable Disease (SD) (Disease Control Rate [DCR])

The DCR is defined as the percentage of participants with confirmed soft tissue best overall response of CR, PR, or stable disease (SD) per RECIST 1.1, and do not have concurrent bone disease progression per PCWG3.

Time frame:
From Date of First Dose until Measured Progressive Disease or Death Due to Any Cause (Up To 12.8 Months)
Reported as:
Number · percentage of participants
Percentage of Participants Achieving CR, PR or Stable Disease (SD) (Disease Control Rate [DCR])
percentage of participants200 mg Abemaciclib Twice Daily
Percentage of Participants Achieving CR, PR or Stable Disease (SD) (Disease Control Rate [DCR])45.5 (30.7 to 60.2)
SecondaryTime to Prostate-Specific Antigen (PSA) Progression

Time to PSA progression is defined as the time from the date of treatment initiation to the date of first observation of PSA progression. The PSA progression is defined as a greater than or equal to (\>=) 25 percentage (%) increase and an absolute increase of \>=2 nanogram/milliliter (ng/mL) above the nadir (or baseline value if baseline is the smallest on study), which is confirmed by a second value obtained 3 or more weeks later.

Time frame:
From Date of First Dose until Confirmed PSA Progression (Up To 12.8 Months)
Reported as:
Median · months
Time to Prostate-Specific Antigen (PSA) Progression
months200 mg Abemaciclib Twice Daily
Time to Prostate-Specific Antigen (PSA) Progression6.5 (3.2 to NA)
SecondaryPercentage of Participants Who Achieved Prostate-Specific Antigen (PSA) Response (PSA Response Rate)

The PSA response rate is defined as the percentage of participants with a reduction in PSA level ≥50% from baseline, confirmed with a second assessment conducted at least 3 weeks later.

Time frame:
From Date of First Dose until Confirmed PSA Progression (Up To 12.8 Months)
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Prostate-Specific Antigen (PSA) Response (PSA Response Rate)
percentage of participants200 mg Abemaciclib Twice Daily
Percentage of Participants Who Achieved Prostate-Specific Antigen (PSA) Response (PSA Response Rate)4.6
SecondaryTime to Symptomatic Progression

Time to symptomatic progression is defined as the time from first dose to any of the following (whichever occurred earlier): 1) symptomatic skeletal event, defined as symptomatic fracture, surgery, or radiation to bone, or spinal cord compression; 2) pain progression or worsening of disease-related symptoms requiring initiation of a new systemic anticancer therapy; and 3) development of clinically significant symptoms due to locoregional tumor progression requiring surgical intervention or radiation therapy. For participants who were not known to have symptomatic progression at the time of data analysis, data were censored on the last date at which no symptomatic progression was indicated.

Time frame:
From Date of First Dose until Symptomatic Progression (Up to 12.8 Months)
Reported as:
Median · months
Time to Symptomatic Progression
months200 mg Abemaciclib Twice Daily
Time to Symptomatic Progression4.1 (3.7 to NA)
SecondaryPharmacokinetics (PK): Maximum Plasma Concentration at Steady State (Cmax,ss) of Abemaciclib

PK: Cmax,ss of abemaciclib is reported. The cycle length was 28 days.

Time frame:
Cycle (C) 1 Day (D) 1: Post dose; C1 D15, C2D1, C2D15, C3D1: Pre dose
Reported as:
Geometric mean · nanogram per milliliter (ng/ mL)
Pharmacokinetics (PK): Maximum Plasma Concentration at Steady State (Cmax,ss) of Abemaciclib
nanogram per milliliter (ng/ mL)200 mg Abemaciclib Twice Daily
Pharmacokinetics (PK): Maximum Plasma Concentration at Steady State (Cmax,ss) of Abemaciclib223 ± 47
SecondaryPK: Minimum/Trough Concentration at Steady State (Cmin,ss) of Abemaciclib

PK: Cmin,ss of abemaciclib is reported.

Time frame:
C1 D1: Post dose; C1 D15, C2D1, C2D15, C3D1: Pre dose
Reported as:
Geometric mean · ng/mL
PK: Minimum/Trough Concentration at Steady State (Cmin,ss) of Abemaciclib
ng/mL200 mg Abemaciclib Twice Daily
PK: Minimum/Trough Concentration at Steady State (Cmin,ss) of Abemaciclib176 ± 37
SecondaryPK: Maximum Plasma Concentration at Steady State (Cmax,ss) of Abemaciclib Metabolites (Total Active Species)

PK: Cmax,ss of abemaciclib metabolites (Total Active Species) is reported.

Time frame:
C1 D1: Post dose; C1 D15, C2D1, C2D15, C3D1: Pre dose
Reported as:
Geometric mean · micromolar per liter (µmol/L)
PK: Maximum Plasma Concentration at Steady State (Cmax,ss) of Abemaciclib Metabolites (Total Active Species)
micromolar per liter (µmol/L)200 mg Abemaciclib Twice Daily
PK: Maximum Plasma Concentration at Steady State (Cmax,ss) of Abemaciclib Metabolites (Total Active Species)1.7 ± 79
SecondaryPK: Minimum/Trough Concentration at Steady State (Cmin,ss) of Abemaciclib Metabolites (Total Active Species)

PK: Cmin,ss of abemaciclib metabolites (Total Active Species) is reported.

Time frame:
C1 D1: Post dose; C1 D15, C2D1, C2D15, C3D1: Pre dose
Reported as:
Geometric mean · µmol/L
PK: Minimum/Trough Concentration at Steady State (Cmin,ss) of Abemaciclib Metabolites (Total Active Species)
µmol/L200 mg Abemaciclib Twice Daily
PK: Minimum/Trough Concentration at Steady State (Cmin,ss) of Abemaciclib Metabolites (Total Active Species)1.5 ± 80
SecondaryPercentage of Participants With Expression of Ki-67 Proliferation Marker by Immunohistochemistry (IHC)

Percentage of participants with expression of Ki-67 proliferation marker at baseline by immunohistochemistry. Baseline expression of the Ki-67 proliferation marker was evaluated by IHC utilizing a 20% or higher score to define high Ki-67 expression. The percentage of Ki-67 positive cells was defined by the number of non-apoptotic tumor cells with unequivocal brown nuclear staining (intensities ≥1 using a 0-3 scale) over the total number of non-apoptotic tumor cells. Unit of Measure is percentage of participants with low or high baseline Ki-67 expression.

Time frame:
Baseline
Reported as:
Number · Percentage of participants
Percentage of Participants With Expression of Ki-67 Proliferation Marker by Immunohistochemistry (IHC)
Percentage of participants200 mg Abemaciclib Twice Daily
Low baseline Ki-67 expression25.8
High baseline Ki-67 expression74.2

Adverse events

Collected over Baseline Up to 28 Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
200 mg Abemaciclib Twice Daily31/44 (70.5%)18/44 (40.9%)42/44 (95.5%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
Event200 mg Abemaciclib Twice Daily
PyrexiaGeneral disorders3/44
Renal failureRenal and urinary disorders3/44
AnaemiaBlood and lymphatic system disorders2/44
Blood creatinine increasedInvestigations2/44
Myocardial infarctionCardiac disorders1/44
DiplopiaEye disorders1/44
DiarrhoeaGastrointestinal disorders1/44
HaemoperitoneumGastrointestinal disorders1/44
General physical health deteriorationGeneral disorders1/44
PainGeneral disorders1/44
Most frequent other events
Showing 10 of 27
Most frequent other events
Event200 mg Abemaciclib Twice Daily
DiarrhoeaGastrointestinal disorders36/44
AstheniaGeneral disorders24/44
Decreased appetiteMetabolism and nutrition disorders24/44
NauseaGastrointestinal disorders21/44
AnaemiaBlood and lymphatic system disorders16/44
VomitingGastrointestinal disorders16/44
NeutropeniaBlood and lymphatic system disorders13/44
ConstipationGastrointestinal disorders9/44
Blood creatinine increasedInvestigations7/44
Back painMusculoskeletal and connective tissue disorders7/44

Baseline characteristics

All participants who received at least one dose of the study drug.

Age, Continuous
Age, Continuous(years)200 mg Abemaciclib Twice Daily
Mean68.3 ± 9.2
Sex: Female, Male
Sex: Female, Male(Participants)200 mg Abemaciclib Twice Daily
Female0
Male44
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)200 mg Abemaciclib Twice Daily
Hispanic or Latino0
Not Hispanic or Latino3
Unknown or Not Reported41
Race (NIH/OMB)
Race (NIH/OMB)(Participants)200 mg Abemaciclib Twice Daily
American Indian or Alaska Native3
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White27
More than one race0
Unknown or Not Reported14
Region of Enrollment
Region of Enrollment(participants)200 mg Abemaciclib Twice Daily
France14
Spain27
United States3
08

Study locations

14 sites
  • University of Utah - Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
  • Centre Leon Berard
    Lyon Cedex 08, 69373, France
  • Institut Paoli-Calmettes
    Marseille, 13273, France
  • Hopital Europeen Georges Pompidou
    Paris, 75015, France
  • Institut Claudius Regaud
    Toulouse cedex 9, 31059, France
  • Gustave Roussy
    Villejuif Cedex, 94805, France
  • Institut Catala d'Oncologia
    L'Hospitalet de Llobregat, Barcelona 08907, Spain
  • Corporacion Sanitaria Parc Tauli
    Sabadell, Barcelona 08208, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, 08025, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital General Universitario Gregorio Maranon
    Madrid, 28007, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Apr 2022, 15 months.

Results were first posted in May 2023, 1 year after primary completion.

Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's 15 months is below that.

Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2020
First posted
May 29, 2020
StartActual
Jan 20, 2021
Primary completionActual
Apr 27, 2022
CompletionActual
Jun 2, 2023
Results first posted
May 24, 2023
Last update
Jun 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04408924
Responsible party
Sponsor
First posted
May 29, 2020
Start date
Jan 20, 2021
Primary completion
Apr 27, 2022
Completion
Jun 2, 2023
Results posted
May 24, 2023
Last update
Jun 25, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abemaciclib

Start the discussion